UB Paderborn / Katalog / Suche / in CDI

Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study

The Lancet (British edition), 2013-06, Vol.381 (9883), p.2091-2099

2013

Volltextzugriff (PDF)

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

The Lancet (British edition), 2008-08, Vol.372 (9639), p.646-655

2008

Volltextzugriff (PDF)

Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study

Clinical pharmacology and therapeutics, 2015-10, Vol.98 (4), p.406-416

2015

Volltextzugriff (PDF)

Using a count of neonatal morbidities to predict poor outcome in extremely low birth weight infants: added role of neonatal infection

Pediatrics (Evanston), 2009-01, Vol.123 (1), p.313

2009

Volltextzugriff (PDF)

Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial

AIDS (London), 2010-01, Vol.24 (1), p.55-65

2010

Volltextzugriff (PDF)

Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis

The lancet HIV, 2015-02, Vol.2 (2), p.e42-e51

2015

Volltextzugriff (PDF)

Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial

AIDS research and human retroviruses, 2012-05, Vol.28 (5), p.437

2012

Volltextzugriff (PDF)

Efavirenz versus Boosted Atazanavir or Zidovudine and Abacavir in Antiretroviral Treatment-Naive, HIV-Infected Subjects: Week 48 Data from the Altair Study

Clinical infectious diseases, 2010-10, Vol.51 (7), p.855-864

2010

Volltextzugriff (PDF)

Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial

PloS one, 2016, Vol.11 (1), p.e0144917-e0144917

2016

Volltextzugriff (PDF)

Improvement in lipid profiles in antiretroviral-experienced HIV-positive patients with hyperlipidemia after a switch to unboosted atazanavir

Journal of acquired immune deficiency syndromes (1999), 2009-06, Vol.51 (2), p.153

2009

Volltextzugriff (PDF)

The Surgical Treatments Outcomes Project for Dysfunctional Uterine Bleeding: summary of an Agency for Health Research and Quality-sponsored randomized trial of endometrial ablation versus hysterectomy for women with heavy menstrual bleeding

Menopause (New York, N.Y.), 2011-04, Vol.18 (4), p.445

2011

Volltextzugriff (PDF)

Gastrointestinal tolerability and quality of life in antiretroviral-naïve HIV-1-infected patients: data from the CASTLE study

AIDS care, 2010-06, Vol.22 (6), p.677-686

2010

Volltextzugriff (PDF)

Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load

AIDS (London), 2003-04, Vol.17 (6), p.831-840

2003

Volltextzugriff (PDF)

A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the combine study)

Antiviral therapy, 2002-06, Vol.7 (2), p.81-90

2002

Volltextzugriff (PDF)

Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial

The Lancet infectious diseases, 2014-07, Vol.14 (7), p.572-580

2014

Volltextzugriff (PDF)

A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients : the MaxCmin2 trial

Antiviral therapy, 2005-01, Vol.10 (6), p.735-743

2005

Volltextzugriff (PDF)

Health-related quality of life in HIV patients switching to twice-daily indinavir/ritonavir regimen or continuing with three-times-daily indinavir-based therapy

Antiviral therapy, 2004-12, Vol.9 (6), p.979-985

2004

Volltextzugriff (PDF)

Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load

AIDS (London), 2003-04, Vol.17 (6), p.831-840

2003

Volltextzugriff (PDF)

Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count>or=300 cells/microL who were assigned to 7.5 MIU interleukin-2

HIV medicine, 2007-03, Vol.8 (2), p.112-123

2007

Volltextzugriff (PDF)

Short- and long-term mortality and causes of death in HIV/tuberculosis patients in Europe

The European respiratory journal, 2014-01, Vol.43 (1), p.166-177

2014

Volltextzugriff (PDF)

Continued indinavir (800 mg tid) versus switching to indinavir + ritonavir (800/100 mg bid) in HIV patients having achieved viral load suppression. A randomized study: The BID efficacy and safety trial (BEST)

AIDS (London), 2000-10, Vol.14, p.S7-S8

2000

Volltextzugriff (PDF)

Health care index score and risk of death following tuberculosis diagnosis in HIV-positive patients

The international journal of tuberculosis and lung disease, 2013-02, Vol.17 (2), p.198

2013

Volltextzugriff (PDF)

Brain-stem auditory evoked potentials in human immunodeficiency virus-seropositive patients with and without acquired immunodeficiency syndrome

Archives of neurology (Chicago), 1992-02, Vol.49 (2), p.166

1992

Volltextzugriff (PDF)

Effects of prophylactic indomethacin in extremely low-birth-weight infants with and without adequate exposure to antenatal corticosteroids

Archives of pediatrics & adolescent medicine, 2011-07, Vol.165 (7), p.642

2011

Volltextzugriff (PDF)

AIDS associated non nosgkin lymphomas (NHL): Retrospective analysis

European journal of cancer (1990), 1993, Vol.29, p.S45-S45

1993

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study

Using a count of neonatal morbidities to predict poor outcome in extremely low birth weight infants: added role of neonatal infection

Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial

Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis

Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial

Efavirenz versus Boosted Atazanavir or Zidovudine and Abacavir in Antiretroviral Treatment-Naive, HIV-Infected Subjects: Week 48 Data from the Altair Study

Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial

Improvement in lipid profiles in antiretroviral-experienced HIV-positive patients with hyperlipidemia after a switch to unboosted atazanavir

The Surgical Treatments Outcomes Project for Dysfunctional Uterine Bleeding: summary of an Agency for Health Research and Quality-sponsored randomized trial of endometrial ablation versus hysterectomy for women with heavy menstrual bleeding

Gastrointestinal tolerability and quality of life in antiretroviral-naïve HIV-1-infected patients: data from the CASTLE study

Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load

A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the combine study)

Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial

A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients : the MaxCmin2 trial

Health-related quality of life in HIV patients switching to twice-daily indinavir/ritonavir regimen or continuing with three-times-daily indinavir-based therapy

Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load

Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count>or=300 cells/microL who were assigned to 7.5 MIU interleukin-2

Short- and long-term mortality and causes of death in HIV/tuberculosis patients in Europe

Continued indinavir (800 mg tid) versus switching to indinavir + ritonavir (800/100 mg bid) in HIV patients having achieved viral load suppression. A randomized study: The BID efficacy and safety trial (BEST)

Health care index score and risk of death following tuberculosis diagnosis in HIV-positive patients

Brain-stem auditory evoked potentials in human immunodeficiency virus-seropositive patients with and without acquired immunodeficiency syndrome

Effects of prophylactic indomethacin in extremely low-birth-weight infants with and without adequate exposure to antenatal corticosteroids

AIDS associated non nosgkin lymphomas (NHL): Retrospective analysis

Suchergebnisse filtern